ORR was evaluated in different patient categories: patients with NSCLC and EGFR mutation pretreated with chemotherapy or TKI (Aura 2 [32], [30], KCSG-Lu15-09 [31]), irrespective of previous chemotherapy [36], patients that were chemotherapy or TKI-naïve [33,34] and treatment naïve [43]. Here, EGFR is linked to non-small cell lung carcinoma.